Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Predisposing factors for hepatocellular carcinoma recurrence following initial remission after transcatheter arterial chemoembolization.

Douhara A, Namisaki T, Moriya K, Kitade M, Kaji K, Kawaratani H, Takeda K, Okura Y, Takaya H, Noguchi R, Nishimura N, Seki K, Sato S, Sawada Y, Yamao J, Mitoro A, Uejima M, Mashitani T, Shimozato N, Saikawa S, Nakanishi K, Furukawa M, Kubo T, Yoshiji H.

Oncol Lett. 2017 Sep;14(3):3028-3034. doi: 10.3892/ol.2017.6489. Epub 2017 Jun 28.

2.

Acute pancreatitis as a complication of trans-arterial chemoembolization of hepatocellular cancer-case report and review of literature.

Krishnamurthy P, Brown M, Agrawal S, Short RF.

J Gastrointest Oncol. 2017 Feb;8(1):E26-E30. doi: 10.21037/jgo.2017.01.15.

3.

Therapeutic Strategies in HCC: Radiation Modalities.

Gallicchio R, Nardelli A, Mainenti P, Nappi A, Capacchione D, Simeon V, Sirignano C, Abbruzzi F, Barbato F, Landriscina M, Storto G.

Biomed Res Int. 2016;2016:1295329. doi: 10.1155/2016/1295329. Epub 2016 Aug 3. Review.

4.

A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis.

Biselli M, Conti F, Gramenzi A, Frigerio M, Cucchetti A, Fatti G, D'Angelo M, Dall'Agata M, Giannini EG, Farinati F, Ciccarese F, Andreone P, Bernardi M, Trevisani F.

Br J Cancer. 2015 Jan 6;112(1):69-76. doi: 10.1038/bjc.2014.536. Epub 2014 Oct 14.

5.

Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations.

Boily G, Villeneuve JP, Lacoursière L, Chaudhury P, Couture F, Ouellet JF, Lapointe R, Goulet S, Gervais N; Comité de l'évolution des pratiques en oncologie.

HPB (Oxford). 2015 Jan;17(1):52-65. doi: 10.1111/hpb.12273. Epub 2014 Jun 24. Review.

6.

Risk factors and therapeutic results of early local recurrence after transcatheter arterial chemoembolization.

Rou WS, Lee BS, Moon HS, Lee ES, Kim SH, Lee HY.

World J Gastroenterol. 2014 Jun 14;20(22):6995-7004. doi: 10.3748/wjg.v20.i22.6995.

7.

Transarterial chemoembolization in patients with hepatocellular carcinoma: predictors of survival.

Sawhney S, Montano-Loza AJ, Salat P, McCarthy M, Kneteman N, Meza-Junco J, Owen R.

Can J Gastroenterol. 2011 Aug;25(8):426-32.

8.

Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma.

Yeh CT, Chen HC, Sung CM, Hsu CL, Lin CC, Pan KT, Tseng JH, Hung CF.

BMC Cancer. 2011 Mar 31;11:117. doi: 10.1186/1471-2407-11-117.

9.

Multivariate analysis of the predictors of survival for patients with hepatocellular carcinoma undergoing transarterial chemoembolization: focusing on superselective chemoembolization.

Ji SK, Cho YK, Ahn YS, Kim MY, Park YO, Kim JK, Kim WT.

Korean J Radiol. 2008 Nov-Dec;9(6):534-40. doi: 10.3348/kjr.2008.9.6.534.

10.

Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma.

Becker G, Soezgen T, Olschewski M, Laubenberger J, Blum HE, Allgaier HP.

World J Gastroenterol. 2005 Oct 21;11(39):6104-9.

11.

Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective.

Poon RT, Fan ST, Tsang FH, Wong J.

Ann Surg. 2002 Apr;235(4):466-86. Review.

12.

Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial.

Kawata S, Yamasaki E, Nagase T, Inui Y, Ito N, Matsuda Y, Inada M, Tamura S, Noda S, Imai Y, Matsuzawa Y.

Br J Cancer. 2001 Apr 6;84(7):886-91.

13.

Prognostic factors after hepatic resection for hepatocellular carcinoma associated with Child-Turcotte class B and C cirrhosis.

Nagasue N, Kohno H, Tachibana M, Yamanoi A, Ohmori H, El-Assal ON.

Ann Surg. 1999 Jan;229(1):84-90.

Supplemental Content

Support Center